Skip to content

Study · Systematic review · 2026

6 results

Nutritional intake changes during GLP-1 receptor agonist therapy: A systematic review and meta-analysis.

Quan AT, Nguyen HL, Nguyen TMT

Diabetes & metabolic syndrome25 Jul 2026

PMID42508090 (opens in a new tab)DOI10.1016/j.dsx.2026.103466 (opens in a new tab)PepBankPUB-42508090
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In adults, the difference in lunch energy intake between semaglutide and tirzepatide was not significant.

    In plain wordsIn adults, semaglutide and tirzepatide did not differ significantly in how much they reduced lunch intake.

    Peptide
    Semaglutide
    Outcome
    No significant changeAd libitum lunch energy intake
    Study

    n: not reported in source

    Comparator
    Tirzepatide
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The semaglutide-versus-tirzepatide difference was not significant (p = 0.154).
    1 context sentence
    Summary · context
    Randomized or crossover placebo-controlled trials lasting at least four weeks that reported standardized ad libitum lunch intake were pooled using a DerSimonian-Laird random-effects model.
  2. 02HumanSystematic reviewEfficacy outcome

    In adults, the difference in lunch energy intake between tirzepatide and semaglutide was not significant.

    In plain wordsIn adults, tirzepatide and semaglutide did not differ significantly in how much they reduced lunch intake.

    Peptide
    Tirzepatide
    Outcome
    No significant changeAd libitum lunch energy intake
    Study

    n: not reported in source

    Comparator
    Semaglutide
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The semaglutide-versus-tirzepatide difference was not significant (p = 0.154).
    1 context sentence
    Summary · context
    Randomized or crossover placebo-controlled trials lasting at least four weeks that reported standardized ad libitum lunch intake were pooled using a DerSimonian-Laird random-effects model.

Studies that did not test the peptide alone4

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 03HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In adults, pooled GLP-1 and dual GIP/GLP-1 receptor agonists (including semaglutide) lowered ad libitum lunch energy intake versus placebo (-1132 kJ).

    In plain wordsIn adults, pooled GLP-1 drugs, semaglutide among them, reduced how much people ate at a test lunch compared with placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseAd libitum lunch energy intake
    Study

    n = 209

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Appetite and food intake · Metabolic and weight

    Measurements

    Pooled treatment difference in lunch energy intake
    −1132 kJ
    pooled GLP-1 and dual GIP/GLP-1 receptor agonists versus placebo

    Source sentences

    Summary
    The pooled treatment difference in ad libitum lunch energy intake was -1132 kJ (95% confidence interval [CI] -1449 to -815), approximately -271 kcal, with no heterogeneity (I-squared = 0%; 95% prediction interval -1828 to -436 kJ).
    1 context sentence
    Summary · context
    Randomized or crossover placebo-controlled trials lasting at least four weeks that reported standardized ad libitum lunch intake were pooled using a DerSimonian-Laird random-effects model.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  2. 04HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome

    In adults, pooled GLP-1 and dual GIP/GLP-1 receptor agonists (including tirzepatide) lowered ad libitum lunch energy intake versus placebo (-1132 kJ).

    In plain wordsIn adults, pooled GLP-1 drugs, tirzepatide among them, reduced how much people ate at a test lunch compared with placebo.

    Peptide
    Tirzepatide
    Outcome
    DecreaseAd libitum lunch energy intake
    Study

    n = 209

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Appetite and food intake · Metabolic and weight

    Measurements

    Pooled treatment difference in lunch energy intake
    −1132 kJ
    pooled GLP-1 and dual GIP/GLP-1 receptor agonists versus placebo

    Source sentences

    Summary
    The pooled treatment difference in ad libitum lunch energy intake was -1132 kJ (95% confidence interval [CI] -1449 to -815), approximately -271 kcal, with no heterogeneity (I-squared = 0%; 95% prediction interval -1828 to -436 kJ).
    1 context sentence
    Summary · context
    Randomized or crossover placebo-controlled trials lasting at least four weeks that reported standardized ad libitum lunch intake were pooled using a DerSimonian-Laird random-effects model.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  3. 05HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In adults, adding a phase 1 trial to the pooled GLP-1 and dual GIP/GLP-1 receptor agonist analysis (including semaglutide) increased the effect on lunch energy intake to -1421 kJ, with substantial heterogeneity.

    In plain wordsIn adults, adding a short phase 1 trial made the pooled GLP-1 drug effect on lunch intake larger, but the trials differed more.

    Peptide
    Semaglutide
    Outcome
    DecreaseAd libitum lunch energy intake
    Study

    n: not reported in source

    Analysis
    Exploratory
    Outcome group
    Appetite and food intake · Metabolic and weight

    Measurements

    Pooled treatment difference in lunch energy intake
    −1421 kJ
    pooled analysis with phase 1 trial (k = 5)

    Source sentences

    Summary
    Adding the phase 1 trial (k = 5) increased the effect to -1421 kJ
    1 context sentence
    Summary · context
    Randomized or crossover placebo-controlled trials lasting at least four weeks that reported standardized ad libitum lunch intake were pooled using a DerSimonian-Laird random-effects model.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  4. 06HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome

    In adults, adding a phase 1 tirzepatide trial to the pooled GLP-1 and dual GIP/GLP-1 receptor agonist analysis increased the effect on lunch energy intake to -1421 kJ, with substantial heterogeneity.

    In plain wordsIn adults, adding a short phase 1 trial made the pooled GLP-1 drug effect on lunch intake larger, but the trials differed more.

    Peptide
    Tirzepatide
    Outcome
    DecreaseAd libitum lunch energy intake
    Study

    n: not reported in source

    Analysis
    Exploratory
    Outcome group
    Appetite and food intake · Metabolic and weight

    Measurements

    Pooled treatment difference in lunch energy intake
    −1421 kJ
    pooled analysis with phase 1 trial (k = 5)

    Source sentences

    Summary
    Adding the phase 1 trial (k = 5) increased the effect to -1421 kJ
    1 context sentence
    Summary · context
    Randomized or crossover placebo-controlled trials lasting at least four weeks that reported standardized ad libitum lunch intake were pooled using a DerSimonian-Laird random-effects model.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:07 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.